TABLE 1.
Characteristic | Value
|
|||
---|---|---|---|---|
Group 1 (200 mg q.i.d./ 400 mg b.i.d.) (n = 35) | Group 2 (400 mg q.i.d./ 600 mg b.i.d.) (n = 31) | Group 3 (800 mg b.i.d./ 800 mg q.d.) (n = 32) | Total (n = 98) | |
Mean age [yr (range)] | 45.3 (18-73) | 49.2 (20-73) | 51.2 (20-74) | 48.4 (18-74) |
Age (yr) | ||||
≥18 to <65 [n (%)] | 30 (86) | 27 (87) | 26 (81) | 83 (85) |
≥65 [n (%)] | 5 (14) | 4 (13) | 6 (19) | 15 (15) |
Sex [n (%)] | ||||
Female | 14 (40) | 14 (45) | 10 (31) | 38 (39) |
Male | 21 (60) | 17 (55) | 22 (69) | 60 (61) |
Race [n (%)] | ||||
Caucasian | 32 (91) | 31 (100) | 27 (84) | 90 (92) |
Other | 3 (9) | 0 | 5 (16) | 8 (8) |
Mean wt [kg (range)] | 71.7 (49.8-111.0) | 74.6 (52.8-112.4) | 74.7 (49.3-101.0) | 73.6 (49.3-112.4) |
Primary diagnosis | ||||
FN | 23 (66) | 21 (68) | 22 (69) | 66 (67) |
rIFI | 12 (34) | 10 (32) | 10 (31) | 32 (33) |